Positive clinical outcome with IVIg as monotherapy in recurrent pemphigoid gestationis.
Int Immunopharmacol
; 26(1): 1-3, 2015 May.
Article
in En
| MEDLINE
| ID: mdl-25765353
Pemphigoid gestationis (PG) is an autoimmune blistering disease associated with pregnancy. It is characterized by the presence of autoantibodies against bullous pemphigoid antigens in the basement membrane zone. A 32 year old female developed PG in the first pregnancy and had a stillbirth. PG recurred during the second trimester of her second pregnancy. Systemic corticosteroid therapy was cause for concern since patient developed gestational diabetes. Patient was unwilling to use insulin. Intravenous immunoglobulin (IVIg) was used as a treatment of last resort. The dose was 2g/kg/cycle. It was given every two weeks antepartum and every three weeks for three months postpartum. PG improved within four weeks of IVIg therapy. Serum and tissue immunopathological studies were negative prior to delivery. A healthy neonate was born. No adverse events to IVIg were observed. No disease was observed ten months postpartum.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pemphigoid Gestationis
/
Immunoglobulins, Intravenous
/
Immunologic Factors
Limits:
Adult
/
Female
/
Humans
/
Pregnancy
Language:
En
Journal:
Int Immunopharmacol
Journal subject:
ALERGIA E IMUNOLOGIA
/
FARMACOLOGIA
Year:
2015
Document type:
Article
Affiliation country:
Estados Unidos
Country of publication:
Países Bajos